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Abstract
Background: Alternative splicing across exon 11 produces several BRCA1 isoforms. Their proportion varies during the cell
cycle, between tissues and in cancer suggesting functional importance of BRCA1 splicing regulation around this exon.
Although the regulatory elements driving exon 11 splicing have never been identified, a selective constraint against
synonymous substitutions (silent nucleotide variations that do not alter the amino acid residue sequence) in a critical region
of BRCA1 exon 11 has been reported to be associated with the necessity to maintain regulatory sequences.
Methodology/Principal Findings: Here we have designed a specific minigene to investigate the possibility that this bias in
synonymous codon usage reflects the need to preserve the BRCA1 alternative splicing program. We report that in-frame
deletions and translationally silent nucleotide substitutions in the critical region affect splicing regulation of BRCA1 exon 11.
Conclusions/Significance: Using a hybrid minigene approach, we have experimentally validated the hypothesis that the
need to maintain correct alternative splicing is a selective pressure against translationally silent sequence variations in the
critical region of BRCA1 exon 11. Identification of the trans-acting factors involved in regulating exon 11 alternative splicing
will be important in understanding BRCA1-associated tumorigenesis.
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Introduction
Pathogenic mutations in the BRCA1 gene are associated with a
high risk of breast and ovarian cancer. Women heterozygous for
such mutations have a lifetime risk of up to around 80% of
developing breast cancer and up to 40% of developing ovarian
cancer [1]. The effects of common deleterious mutations, such as
exonic insertions and deletions, nonsense substitutions and
substitutions at invariant consensus splice sites (AG and GT), are
relatively easy to predict. However, the effects of synonymous,
translationally silent substitutions on splicing are generally much
less well understood and require investigation through functional
studies. Such substitutions are called ‘silent’ as they do not directly
change the amino acid sequence of the protein. However, these
synonymous substitutions (as well as non synonymous substitu-
tions) can still have a deleterious effect at the RNA level by
creating or disrupting secondary structures or regulatory sequenc-
es. This in turn may alter splicing fidelity, with consequent loss of
function or production of new antagonistic protein isoforms.
BRCA1 is known to undergo alternative splicing of a number of
its exons, including the large and functionally important exon 11
[2]. Alternative splicing of exon 11 yields a full length isoform (FL)
and also shorter isoforms through use of an alternative intra-
exonic splice donor site, D(11q), or through complete skipping of
exon 11, D(11). Alternative splicing can also exclude exons 9 and
10 from the mature mRNA, D(9,10). These isoforms maintain the
original BRCA1 open reading frame and allow functional protein
production.
The control of the ratio of splicing isoforms produced within a
cell requires regulation by trans-acting splicing factors that
recognise and bind specific pre-mRNA sequences. Their expres-
sion changes in cancer as well as in different tissues [3,4]. Since
BRCA1 isoforms vary in quantity during the cell cycle and within
different tissues [5–8], including tumour tissue, it is expected that
important splicing regulatory elements may be found at critical
gene regions (e.g. within exon 11) that allow the binding of
relevant splicing factors. Mutations in these sequence elements
would disrupt normal splicing and potentially lead to disease.
Therefore there would be an evolutionary selection pressure not
only against codon-altering mutations but also against synonymous
mutations at these sites. This process, known as purifying selection,
is thought to explain the bias in synonymous codon usage observed
at specific genomic sites across evolutionarily divergent species.
The observation of purifying selection at translationally silent sites
may therefore reflect the presence of splicing regulatory elements
or regions of critical RNA secondary structure [9–10].
A bias towards the usage of particular codons, rather than their
synonymous counterparts, has previously been reported in a
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end of exon 11 [11]. Several ‘hotspots’ (codons 195, 196, 215, 231,
244 and 313) have been identified around this critical region [11].
These are putative sites of purifying selection with a high ratio of
nonsynonymous to synonymous substitutions.
In order to investigate BRCA1 splicing involving exon 11, we
developed a minigene incorporating the whole of BRCA1 exons 8
to 11 and part of exon 12. Using this hybrid minigene approach,
we have experimentally validated the hypothesis that maintenance
of correct alternative splicing is the cause of selection against silent
sequence variations in the BRCA1 critical region spanning exon
11.
Results
Minigene splicing assay for BRCA1 exon 11
In order to assay the effects of synonymous substitutions on
BRCA1 splicing, we constructed a pB1 wild-type minigene that
incorporated sequence from BRCA1 exon 8 up to the first 89
nucleotides of exon 12 (Figure 1a). Intronic sequences were
shortened but still contained at least 190 nucleotides of native
intronic sequence at either end. Intron 8 is 460 bp (original size
2485 bp); Intron 9 is 379 bp (original size 1321 bp); Intron 10 is
684 bp (original size 985 bp); Intron 11 is 402 bp (original size
402 bp). The pB1 minigene was transiently transfected into MCF7
breast cancer cell lines. RNA was extracted and minigene-specific
cDNA synthesised using the specific primer pCSrev. BRCA1
splicing products were analysed by RT-PCR using primers specific
for BRCA1 FL, D(11) and D(11q) isoforms (Figure 1b). Electro-
phoresis of RT-PCR BRCA1 splicing products revealed the
presence of the three isoforms FL, D(11) and D(11q); showing
comparable outcomes with that of endogenous BRCA1 in non-
transfected MCF7 cells (Figure 1c). In order to validate the
minigene for splicing assays, we introduced the nucleotide
substitution c.696A.G previously reported to affect exon 11
splicing. As shown in Figure 1c, introduction of this change to the
minigene caused an increase of the D(11) isoform as described in
the literature [12].
The c.696A.G mutated minigene was also tested in normal
mammary epithelial cells (HMEpC, invitrogen) and breast cancer
cells MDA-MB-231 (ATCC). All cell lines tested resembled the
increase in D11 isoform observed in MCF7 cells (data not shown).
Furthermore, a minigene construct containing the genomic
sequence from exons 9–12 had the same pattern of splicing
Another version of the minigene behaved in exactly the same
manner when we inserted the entire genomic sequence from exons
9 to 12 (data not shown).
Synonymous substitutions of codons thought to
undergo purifying selection
Mutations at codons 195, 196, 215, 231, 244 and 313 (which
are proposed to exhibit purifying selection) were assayed for their
effect on BRCA1 splicing. 13 synonymous substitutions were
introduced by site-directed mutagenesis (Supporting Table S1):
The resulting mutated minigenes were transiently transfected
into MCF7 cell lines and splicing analysed as described (Figure 2).
Mutations that do not affect splicing would be expected to give a
similar isoform band pattern to the wild-type sequence. If splicing
of exon 11 is affected, a relative decrease of one isoform should be
accompanied by a reciprocal increase in one or more of the other
isoforms, or the appearance of a novel isoform. In addition one or
more new isoforms could appear.
All three synonymous substitutions at codon 231 appear to alter
splicing. These changes lie 23 nucleotides distal to the start of exon
11 and significantly reduce the levels of FL and D(11q) in favour of
increased levels of D(11) isoform. This suggests that sequence
changes at this site alter the splicing of exon 11, through reduced
recognition of the intron 10 acceptor site, resulting in its exclusion
from the final mRNA. This finding points towards an important
sequence element, such as an exonic splicing enhancer, located
around codon 231.
Codon 244 lies 60 nucleotides downstream from the start of
exon 11 and is 55 nucleotides proximal to the 11q splice donor
site. The T.C synonymous substitution at the third position of
this codon seems to enhance levels of the D(11q) isoform. A similar
effect was also observed in normal mammary epithelial cells
(HMEpC supplied by ECACC) (data not shown).
Codon 313 is situated 150 nucleotides 39 (downstream) of the
11q splice donor site. Synonymous mutations in this codon do not
appear to alter exon 11 splicing. Codons 195 and 196 are 9 and 6
nucleotides away from the 39 end of exon 9 respectively and
synonymous mutations at these sites would therefore most likely
affect splicing of exon 9. Codon 215 lies 23 nucleotides from the 39
end of exon 10 and so any splicing effects may be expected to
affect this exon. Our assay does not show any significant alteration
in relative exon 11 splice isoform abundance with synonymous
mutations at these sites. We therefore evaluated their effect on
skipping of exon 9 and 10. Splicing products revealed presence of
four isoforms {FL, D(9), D(10) and D(9&10)} showing comparable
outcomes with that of the pB1WT minigene (supporting figure S1).
Other synonymous changes reported in breast cancer
patients
Since the c.693G.A substitution at codon 231 affects splicing
of BRCA1 exon 11 and has previously been reported in a patient
with breast cancer [12], we decided to evaluate the effects of
additional synonymous substitutions in BRCA1 exon 11
(c.825C.T codon 275, c.828A.G codon 276 and c.795T.C
codon 265; supporting table S1) that had been identified in
patients with breast cancer ascertained by the local regional
genetics service in whom no other pathogenic mutation had been
found. After introducing the substitutions into the minigene,
MCF7 cell lines were transfected and RNA analysed for FL,
D(11q) and D(11) isoforms.
The T.C substitution within codon 265 lies just 8 nucleotides
39 of the 11q splice donor site. Alteration of the native sequence
GTAGTTCT to GTAGTTCC results in reduction of the D(11q)
isoform (Figure 3 and supporting table S1). This suggests that the
sequence at codon 265 influences the use of this alternative splice
site. The proximity to the splice donor site makes it likely that the
sequence forms part of the splice site itself. The mutation appears
to weaken the splice site, decreasing its usage. The synonymous
substitution in codon 275 lies 38 nucleotides 39 of the 11q splice
donor site. Its presence appears to increase the relative amount of
D(11q) while decreasing the FL isoform but not D(11)(Figure 3 and
supporting table S1). This suggests that the substitution favours the
usage of D11(q) donor site competing with the FL isoform donor
site. The substitution in codon 276 just 3 nucleotides further
downstream does not seem to have this same effect. This suggests
that codon 276 contains an important sequence element such as
an ESE that favours use of the D(11q) splice site. A similar effect
on splicing for these three synonymous changes was also observed
in HEK 293 cells (data not shown).
D11q intensity seems to be higher in figure 3 than 1 and 2.
Although we observed a certain degree of variability between
biological replicates (at different transfection dates), changes in
isoform proportion (comparing different variants) were consistent.
In addition, we did not observe variability between technical
BRCA1 Exon 11 Splicing Regulatory Regions
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be explained by the fact that the BRCA1 isoform proportions vary
during the cell cycle [5] so that minimal changes in cell status (e.g.
the number of passages) may account for the change in intensity of
D11q isoforms between biological replicates.
In addition, these types of effects should be routinely tested with
quantitative qRT-PCR methods.
Targeted deletions of the critical region
In order to identify putative splicing regulatory elements in the
‘critical region’ of BRCA1 exon 11, we undertook a comparative
genomic analysis of the BRCA1 sequence of 9 eutherian mammals
using the Ensembl genome browser (http://www.ensembl.org/
index.html). The data show several conserved sequences along the
‘critical region’ (supporting Figure S2). In order to evaluate
whether these conserved regions include splicing regulatory
sequences we used SFmap (http://sfmap.technion.ac.il/) [13] for
the prediction of splicing factor binding sites (supporting Figure
S2).
We then performed a pB1 minigene deletion analysis of the
most conserved regions containing putative binding sites for
splicing regulatory proteins. The D1, D2, D3 and D4 deletions are
highlighted in Figure 4a. Hybrid minigenes carrying each deletion
were transiently transfected into MCF7 cells and splicing was
Figure 1. Minigene splicing assay of BRCA1 exon 11. A. The pB1 wild type (WT) version of the minigene is shown. PCMV=promoter of the
pCDNA3 vector. ATG=start codon. TAG=stop codon. +3C=insertion of cytosine as the third nucleotide in exon 8. pA=poly A signal. 1=exon 1 of
the alfa globin gene. BRCA1 exons from 8 to 12 are numbered. The black solid line represents introns. Dotted lines show alternative splicing of exon
11. B. The three splicing isoforms FL, D11q and D11 and the position of specific oligos used for detection, are shown. C. Detection of BRCA1 exon 11
splicing isoforms for: _MCF7 endogenous BRCA1 (endogenous WT). _pB1 WT minigene transfected in MCF7 (pB1 WT). _pB1 minigene carrying the
c.696G.A nucleotide substitution transfected in MCF7 (pB1 c.696G.A).
doi:10.1371/journal.pone.0037255.g001
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splicing is unchanged with deletion D1 and D4. Deletion D3 has a
weak effect in reducing levels of the D(11q) isoform in favour of
D(11). Transfection with the hybrid minigene carrying deletion D2
has the strongest effect, inducing almost complete skipping of exon
11.
The putative splicing factors predicted to bind in D2 and D3 by
SFmap (http://sfmap.technion.ac.il/) and SpliceAid2 (www.
introni.it/spliceaid.html) are shown in supporting Figure S3.
Discussion
That synonymous mutations are under evolutionary constraint
due to splicing requirements has been demonstrated experimen-
tally [14]. Hurst and Pal found a pronounced peak in the ratio of
non-synonymous to synonymous substitutions between codons 200
and 300 of BRCA1 exons 10 and 11 when comparing human/dog
and mouse/rat gene alignments [11]. The presence of this so-
called ‘critical region’ reflects an unusually low rate of transla-
tionally silent synonymous sequence changes, suggesting that
purifying selection may be acting on this region to select against
synonymous changes, possibly in order to preserve splicing
regulatory elements. In this study, we have experimentally verified
this hypothesis by testing synonymous substitutions at codon sites
proposed by Hurst and Pal to have the highest non-synonymous to
synonymous substitution ratios.
Of the 6 codons analysed, only synonymous substitutions at
codon 231 and codon 244 affected splicing of BRCA1 exon 11. The
substitution at codon 244 increased levels of the D(11q) isoform to
thedetrimentofthe fullandD(11)isoforms.However,itisdifficultto
speculate upon the relevance of this aberrant splicing effect. This is
for two main reasons. Firstly, the effect on the splicing ratio is only
relatively weak. Secondly, the D(11q) isoform has been shown to
play a role in apoptosis [15]. However, a recent article has shown
that, following knockdown of the nuclear chaperon Ubc9 (ubiquitin
conjugating enzyme 9), D(11q) accumulation in the cytoplasm
promotes growth and survival of breast cancer cells [16]. This may
signify that an increase of D(11q) isoform may have deleterious
effects in circumstances where Ubc9 is compromised.
Substitutions at codon 231 caused skipping of exon 11 with a
marked increase in amounts of the D(11) isoform. Overexpression of
this isoform in mouse epithelial mammary cells has been shown to
cause atypical duct hyperplasia [17]. This could explain the biased
synonymous codon usage observed at codon 231 and may reflect the
necessity to preserve a regulatory sequence that protects against
aberrant splicing, which would otherwise predispose to breastcancer.
Substitutions at codons 195, 196, 215 and 313 did not have
any discernible effect on isoform levels. However, there may be
other ways by which synonymous changes can exert an effect
[18]. For instance tRNAs complimentary to different codons
vary in their relative concentrations within a cell, meaning that
synonymous codons may not be equally represented in terms of
the relative abundance of their complimentary tRNAs [19]. This
variable cellular availability of specific tRNAs can affect
translational efficiency of protein product.
Nevertheless, the possibility that substitutions at these codon
positions affect regulatory elements of splicing should not be
Figure 4. Minigene splicing assay of BRCA1 exon 11. A. Sequence of the critical region in exon 11 showing the deletion 1,2,3,4 (highlighted).
The donor site (59ss) generating D11q isoform is boxed. Arrows indicate nucleotide positions of the variations reported in Figure 2 and 3 to affect
splicing. B. Transient transfection results for the hybrid minigenes carrying deletions.
doi:10.1371/journal.pone.0037255.g004
Figure 2. Minigene splicing assay of synonymous substitu-
tions. Effect of synonymous BRCA1 substitutions on splicing products
full-length, D(11q) and D(11). RT-PCR products from transfection
experiments using minigenes carrying codon substitution are shown.
doi:10.1371/journal.pone.0037255.g002
Figure 3. Minigene splicing assay of patients synonymous
substitutions. Effect of synonymous BRCA1 substitutions on splicing
products full-length, D(11q) and D(11). RT-PCR products from transfec-
tion experiments using mutated minigenes are shown.
doi:10.1371/journal.pone.0037255.g003
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evolution that compensate for aberrant splicing [14,20].
The c.693G.A substitution at codon 231 has previously been
reported to cause exon 11 skipping in a patient with breast cancer
[12]. This synonymous change in our minigene gave the same
splicing outcome, proving the validity of the pB1 minigene as a
splicing assay for BRCA1 exon 11 variants. We therefore tested
three further synonymous variants found in breast cancer patients
to investigate their effect on BRCA1 splicing. Our findings show
that the mutations c.795T.C and c.825C.T decrease and
increase levels of the D(11q) isoform respectively. However, for the
same reasons mentioned above it is not possible to classify these
variants as pathogenic mutations causing aberrant splicing since
the role of D(11q) is not clear. In fact, the D(11q) isoform has been
described as both causing apoptosis and causing cancer [15,16].
With these opposing roles in mind, we can hypothesise that an
increased abundance of this isoform may have competing and
contrasting effects in controlling cell proliferation or cell death
depending on a patient’s personal sequence context.
Both artificial and natural variants analysed in this study cause
multiple splicing effects (Supporting Table S1). For instance down-
regulation of the D(11q) isoform is not always accompanied by up-
regulation of other isoforms. This suggests that different regulatory
elements are affected that control one or all of the following events:
usage of the exon 11 acceptor site, usage of the exon 11 donor site,
usage of the D(11q) isoform donor site, and competition between
the two donor sites.
Despite the fact that only synonymous substitutions in 2 out of 6
codons affected exon 11 splicing, the deletion analysis of BRCA1
exon 11 appears to experimentally validate the hypothesis that
maintenance of correct alternative splicing is the cause of selection
against silent sequence variations in the BRCA1 critical region. In
fact, 2 out of 4 of these deletions affected the proportion of BRCA1
splicing isoforms. In summary, deletions 2, and 3 changed BRCA1
splicing ratios in different and opposing directions.
Deletion 2, in particular, caused almost complete skipping of
exon 11 and was predicted to lose splicing regulatory sequences for
binding of several splicing enhancer proteins (SC35, SRp20/30/
40, NOVA 1 and YB1). Deletion 3, just next to the D(11q) donor
site, decreased D(11q) isoform levels, probably due to the loss of a
putative binding site for TIA1 (a donor site modulator) predicted
by the SpliceAid analysis. NOVA 1 binding was predicted to bind
both regions corresponding to deletion 2 and 3. Binding of
NOVA1 at the end of an exon and beginning of an intron was
proposed to induce exon inclusion [21]. In this case binding of
NOVA1 upstream and downstream D11q isoform donor site
might regulate production of this isoform.
We did not observe strong correlation on the splicing effect of
nucleotide changes occurring inside the region of deletion 2
(c.732T.C) and deletion 3 (c.825C.T). This suggests that
composite regulatory elements of splicing might be present in this
region of BRCA1 exon 11 as has been previously suggested for
CFTR exon 12 [22].
In order to fully understand the effects of altered splice isoform
ratios in BRCA1-related cancer, it will be necessary to know the
roles of each isoform individually and to understand the combined
roles of different isoforms both in health and in tumorigenesis. Part
of this understanding will require confirmation of which splicing
factors are involved in regulating alternative splicing of BRCA1,
including those suggested by this study that may be involved in the
splicing of exon 11. Knowledge of these mechanisms would
provide a framework for the development of new therapeutic
agents capable of manipulating BRCA1 splicing and treating
BRCA1-related cancers (eg. breast ovarian and prostate cancer). At
some level it may be that cancer predisposition is not so much
down to whether individual isoforms are simply present or absent
but rather that subtle alterations to a complex and nuanced
isoform profile are particularly relevant. Such an isoform
environment may interact with other cellular pathways to make
conditions favourable or otherwise towards tumour development.
If this is the case, it will provide an added challenge of complexity
to our understanding of tumorigenesis. However, it may also allow
novel and innovative approaches to manipulating the cellular
environment in order to prevent and treat cancer.
Materials and Methods
Construction of the minigene
The pB1 WT minigene is shown in Figure 4. It consists of 6
exons (including part of their flanking introns) cloned in a modified
version of the pCDNA3(+) vector (Invitrogen) under the control of
the CMV promoter. The polylinker of the pCDNA3+ vector has
been replaced with an adaptor containing the appropriate
restriction sites for cloning of exon 1 of the a-globin gene with
its 39 flanking intronic region together with the relevant BRCA1
genomic region from exon 8 to exon 12. Introns have been
shortened by PCR amplification with oligonucleotides carrying a
non complementary tail for specific restriction digestion and
subsequent cloning in pCDNA3+.
Exon 1 of the a-globin gene is used as the first exon of the
minigene as it provides a strong splice donor site at its 39 end as
well as an ATG start codon at its 59 end.
Using specific oligonucleotides and a two-step PCR mutagenesis
method [23], a stop codon was created in exon 12 and a single
nucleotide insertion was created in exon 8 in order to maintain the
correct reading frame. Several unique restriction sites are
maintained in the sequence in order to facilitate subsequent
mutagenesis and deletion analysis. Mutated minigenes and
minigenes carrying deletions were generated through a two-step
PCR overlap extension [24] using the pB1 WT construct as a
template. The identity of all minigenes was checked by sequenc-
ing. The minigene complete sequence and oligonucleotidess used
for cloning and mutagenesis are available upon request.
Cell Culture
Human breast cancer cell lines, MCF7 (ATCC number: HTB-
22
TM), were grown in DMEM medium with 4500 mg/L glucose,
pyruvate and L-glutamine supplemented with 1% penicillin/
streptomycin and 10% fetal bovine serum. Cells were incubated at
37uC in a 5% CO2 atmosphere.
Transfection
Minigene plasmid vector was transfected into MCF7 cell lines
using the FuGENE 6 transfection reagent from Roche. 100 mlo f
DMEM serum-free medium containing 2 mg of vector DNA and
3 ml of FuGENE reagent was incubated for 15 minutes at room
temperature before the mixture was added in 6 cm-well cell
cultures (50% confluent) in the presence of 10% fetal bovine
serum.
RNA Extraction and RT-PCR
40 hours after transfection, RNA was extracted from cells using
the RNeasy-plus kit from QIAGEN following the manufacturer’s
instructions. To analyse alternative splicing of BRCA1 exon 11 in
the pB1 minigene, RT-PCR was performed with 1.5 mg of total
RNA using the pCSrev primer [59 GCAACTAGAAGGCA-
CAGTCGAGG 39] to exclusively target only RNA products from
the pB1 minigene. Given the large size of exon 11 (3426
BRCA1 Exon 11 Splicing Regulatory Regions
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following the manufacturer’s instructions. 1/4 of the resulting
cDNA was amplified in a PCR reaction using primers specific for
the desired splice isoforms and PCR products were analysed by gel
electrophoresis in 1.5% agarose. The forward primer [9–10F: 59
ACTTATTGCAGTGTGGGAGA 39] hybridises to the junction
between exons 9 and 10. Reverse primers are a mixture of one
specific for FL [11FLR: 59 GGAGTCCGCCTATCATTACATG
39] and one specific for D(11q) and D(11) [12R: 59 CCA-
GATGCTGCTTCACCCT 39]. 11FLR hybridises within exon 11
distal to the 11q splice site. 12R hybridises to proximal exon 12
and overlaps the exon 10/12 junction and also the exon 11q/12
junction.
For the analysis of BRCA1 alternative splicing of exons 9 and 10,
RT-PCR was performed on 1 mg total RNA using random
primers with the Promega kit. BRCA1-minigene specific PCR was
performed on resulting cDNA using the forward specific primer
alpha-8F [59 GAGGCCCTGGAGAGGAcAA 39] and the reverse
primer 11+81Rev [59 TCTCAGTGGTGTTCAAATCA 39].
Alpha-8F hybridises to the junction between exon 1 of the a-
globin gene and exon 8 of BRCA1. The c nucleotide in lowercase
represents the insertion made in exon 8 of the pB1 minigene.
11+81Rev hybridises to exon 11 upstream of the donor site
producing D(11q).
In order to eliminate heteroduplexes from mixed-template 1/
10
th of PCR products were subjected to ‘reconditioning PCR’ for 6
cycles [25].
In silico analysis
Putative splicing regulatory sequences in BRCA1 exon 11 were
predicted using the computational tools SFmap [13] and
SpliceAid2 [26], which enable accurate prediction and mapping
of known splicing factor binding sites.
The following calculation parameters were chosen for SFmap:
– Scoring function: COS(WR);
– Medium stringency (Threshold [Significant] at p-value,0.005;
[Suboptimal] at p-value,0.05);
– Window size: 50.
Supporting Information
Figure S1 Minigene splicing assay of BRCA1 exon 9 and
10. A. The pB1 wild type (WT) version of the minigene is shown.
PCMV=promoter of the pCDNA3 vector. ATG=start codon.
TAG=stop codon. +3C=insertion of cytosine as the third
nucleotide in exon 8. pA=poly A signal. 1=exon 1 of the alfa
globin gene. BRCA1 exons from 8 to 12 are numbered. The black
solid line represents introns. Dotted lines show alternative splicing
of exon 9 and 10. B. Detection of BRCA1 splicing isoforms FL
(inclusion of exon 9 and 10); D9 (skipping of exon 9); D10
(skipping of exon 10); D9,10 (skipping of exon 9 and 10).
(TIF)
Figure S2 BRCA1 alignments between nine eutherian
mammals. The sequence of exon 11 critical region is in blue.
Black characters represent the last 6 nucleotides of intron 10. The
alternative donor site (59ss) in exon 11 which gives rise to the
D(11q) isoform is in white characters. Red are the nucleotide
variations with respect to the human sequence. Ca.=Canis_fa-
miliaris; Eq.=Equus_caballus; Bo.=Bos_taurus; Ho.=Homo_sa-
piens; Pa.=Pan_troglodytes; Po.=Pongo_pygmaeus; Ma.=Ma-
caca_mulatta; Mu.=Mus_musculus; Ra.=Rattus_norvegicus.
Splicing regulatory proteins (predicted with SFmap) putatively
binding to the human sequence are shown at the top of each
sequence. The one corresponding to splicing regulatory motifs that
are most conserved are highlighted. The list of putative sequences
for splicing regulatory proteins and relative scores as reported in
SFmap are listed.
(DOC)
Figure S3 Splicing factors predicted to bind. The sequence of
deletion 2 and deletion 3 region are shown. Splicing factors
predicted (by SFmap and/or SpliceAid) to bind these regions are
listed.
(XLS)
Table S1 Information about all synonymous variants tested. The
table includes the amino acid number, the nucleotide change, the
dbSNP rs number, genomic location in hg19 coordinates (Chr 17
position),.PMID (for existing PubMed records) and our interpre-
tation of the effects caused by the variations on different splicing
events tested (isoform regulation).
(XLS)
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